) recently announced encouraging data from two phase III studies
(ENGAGE and ENCORE) evaluating the use of its oral candidate,
eliglustat tartrate, for Gaucher disease type I.
The randomized, double-blind, placebo controlled ENGAGE phase III
study enrolled 40 treatment-naïve patients with Gaucher disease
type I. Results from the study revealed a statistically
significant improvement in spleen size at nine months for
patients treated with eliglustat tartrate compared to those in
the placebo arm.
Additionally, improved hemoglobin levels, platelet levels and
liver volumes were observed in patients in the eliglustat
tartrate arm compared to patients treated with placebo.
ASTELLAS PHARMA (ALPMY): Get Free Report
BAYER A G -ADR (BAYRY): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.
Sanofi also reported data from the second phase III study,
ENCORE. The randomized, open-label study enrolled 160 adults with
Gaucher disease type I. The study compared eliglustat tartrate
with Sanofi's Cerezyme, the current standard of care for Gaucher
disease type I. Eliglustat tartrate demonstrated non-inferiority
to Cerezyme and met the primary endpoint of the study.
Eliglustat tartrate, if approved, will provide a convenient
treatment option to Gaucher disease type 1 patients as compared
to Cerezyme, which is administered through intravenous infusions.
We note that Sanofi is looking to develop its pipeline to combat
the generic threat that is faced by several of its products.
Sanofi carries a Zacks Rank #3 (Hold) in the short run. Pharma
companies that currently look better-positioned include
Eli Lilly and Company
). All three companies carry a Zacks Rank #2 (Buy).